Progressively autonomous group (n = 22) | Supervised group (n = 23) | p | |
---|---|---|---|
Age, mean ± SD | 62.5 ± 10.7 | 63.5 ± 8.1 | 0.64 |
Sex, n (%) | 0.58 | ||
Male | 21 (95.5) | 21 (91.3) | |
Female | 1 (4.5) | 2 (8.7) | |
Weight, kg ± SD | 82.4 ± 13.7 | 86.8 ± 12.3 | 0.27 |
BMI, kg/m2 ± SD | 27.1 ± 4.0 | 29.5 ± 4.0 | 0.07 |
AC, cm ± SD | 103.5 ± 12.3 | 106.0 ± 8.7 | 0.45 |
EQ5D, mean ± SD | 0.828 ± 0.181 | 0.791 ± 0.161 | 0.48 |
6MWT distance, meters ±SD | 600.8 ± 84.2 | 524.0 ± 88.1 | 0.0064 |
NYHA, n (%) | |||
I | 11 (52.4) | 6 (27.3) | 0.32 |
II | 7 (33.3) | 11 (50.0) | |
III | 3 (14.3) | 4 (18.2) | |
IV | – | 1 (4.5) | |
Past medical history, n (%) | |||
Diabetes | 4 (18.2) | 3 (14.3) | 0.73 |
Hypertension | 6 (27.3) | 6 (26.1) | 0.79 |
Hyperlipidemia | 16 (72.7) | 15 (65.2) | 0.59 |
Moderate heart failure | 1 (4.5) | 7 (33.3) | 0.0212 |
Myocardial infarction | 5 (22.7) | 9 (40.9) | 0.19 |
Revascularization, n (%) | |||
Angioplasty | 15 (68.2) | 13 (56.5) | 0.42 |
CABG | 3 (13.6) | 4 (19.0) | 0.70 |
Cardiac function, n (%) | |||
LVEF < 50% | 1 (4.8) | 3 (14.3) | 0.13 |
LVEF > 50% | 20 (95.2) | 18 (85.7) | |
Current smokers, n (%) | 4 (18.2) | 3 (14.3) | 0.73 |
Drugs, n (%) | |||
Antiplatelet drugs | 19 (86.4) | 16 (69.6) | 0.17 |
Anticoagulants | – | 4 (19.0) | 0.0485 |
Beta-blockers | 11 (50.0) | 11 (47.8) | 0.88 |